Full Text
HTA128 Reassessment of Orphan Drugs After Exceeding the 50 Mio. Euro Revenue Threshold: Effects on Added Benefit and Price Discount

Abstract

Authors

RO Michel JF Löpmeier A Ingendoh-Tsakmakidis N Italia W Kulp

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×